Detection of Antibodies to Specific Glycans as a Novel Diagnostic Test for Autoimmune Disease
Abstract (Set) JHU scientists have identified biomarkers specific for autoimmune disease. Systemic autoimmune diseases are life- threatening, complex and can involve various organ systems including skin, joints, the renal system, the hematopoietic system, and the cardiovascular system. In autoimmune disorders, antibodies target self-molecules known as autoantigens. The identification of universal and specific autoantigens as diagnostic tools for disorders such as lupus or scleroderma is of great interest. Current diagnostic methods for autoimmune disease require screening for multiple clinical and laboratory parameters. For example, at present there is no single diagnostic test to diagnose lupus. A diagnostic test that provides sensitivity and specificity to the diagnosis of autoimmune diseases, as well as a test that predicts disease severity, outcomes or complications, would be a major advance in the field. JHU scientists have uncovered several antibodies specific for glycan residues found in patients with autoimmune disease. These biomarker antibodies have potential use in a simplified diagnostic assay to meet medical need for reliable biomarkers to assess early autoimmune disease activity. Description (Set) Proposed Use (Set) This technology is based on detection of anti-glycan antibodies in serum samples of patients with autoimmune disorders. It could be commercialized as diagnostic, prognostic and monitoring assay for patients with autoimmune diseases such as lupus or scleroderma.Inventor(s): Bochner, Bruce ,Grader-Beck, Thomas,Rosen, Antony,von Gunten, Stephan
Type of Offer: Licensing
« More Diagnostic Patents